scholarly journals Co-expression of SARS-CoV-2 entry genes in the superficial adult human conjunctival, limbal and corneal epithelium suggests an additional route of entry via the ocular surface

Author(s):  
Joseph Collin ◽  
Rachel Queen ◽  
Darin Zerti ◽  
Birthe Dorgau ◽  
Maria Georgiou ◽  
...  
Ophthalmology ◽  
1995 ◽  
Vol 102 (10) ◽  
pp. 1486-1496 ◽  
Author(s):  
Kazuo Tsubota ◽  
Ikuko Toda ◽  
Hiroshi Saito ◽  
Naoshi Shinozaki ◽  
Jun Shimazaki

2017 ◽  
Vol 86 (7-8) ◽  
Author(s):  
Petra Schollmayer ◽  
Zala Lužnik

Background: Corneal epithelium is renewed by stem cells (SC) that reside at the corneal limbus. Reduced number of SC or their abnormal function lead to the ocular surface disease called limbal stem cell deficiency (LSCD), characterized by corneal conjunctivalization, vascularization, persistent epithelial defects, chronic inflammation, and loss of vision. In a case of total unilateral LSCD, autologous transplantation of limbal epithelial stem cells (LESC) from the healthy eye is needed. We describe the surgical technique of choice for autologous limbal transplantation, called conjunctival limbal autograft (CLAU) that we combined with amniotic membrane (AM) use. We present the results of CLAU in three patients with total unilateral LSCD due to chemical injury.Methods: Autologous limbal transplantation CLAU begins with the removal of fibrovascular pannus from the diseased corneal surface and the harvesting of two conjunctival-limbal grafts from the healthy eye. The grafts are then transplanted on to the limbal area of the recipient eye. AM is used as a patch to cover the denuded cornea and limbal grafts, as well as a barrier preventing the conjunctival epithelium from encroaching on to the temporal and nasal side of the corneal surface. In the donor eye, AM is used to cover the donor sites. CLAU with the use of AM was performed in 3 patients with unilateral LSCD due to chemical eye injury. In one patient limbal transplantation was combined with symblepharon lysis for entropium repair. In all cases AM was removed 3–6 days postoperatively to assess the growth of new epithelium from the limbal grafts. In all patients the ocular surface was covered with another AM until the cornea was completely epithelized and the new epithelium stable. In one patient the corneal regrafting and cataract removal was performed subsequently.Results: CLAU was successful in 2 patients and partially successful in 1 patient during the follow up. In all cases the growth of new epithelium from the limbal grafts was noted on day 3–6 after CLAU. The cornea was completely epithelized within 2 weeks in 2 patients and after 35 days in one patient. In two patients the corneal epithelium remained clear, smooth and stable during the follow up of 3.5 years and 4 months, respectively. In one patient, uneven epithelium probably representing a mosaic of corneal and conjunctival cells was noted in the central corneal region, where a small corneal ulcer developed 5 months after CLAU. In donor eyes no postoperative complications were noted, the donor sites epithelized within few days.Conclusions: Autologous limbal transplantation according to CLAU surgical technique combined with the use of AM is a successful and safe therapy for restoring corneal surface in total unilateral LSCD after chemical injury. It enables further surgical procedures for restoring the vision such as corneal transplantation and cataract surgery.


1995 ◽  
Vol 35 (4) ◽  
pp. 182
Author(s):  
Kazuo Tsubota ◽  
Ikuko Toda ◽  
Hiroshi Saito ◽  
Naoshi Shinozaki ◽  
Jun Shimazaki

2021 ◽  
Vol 99 (S265) ◽  
Author(s):  
Chantal Perrache ◽  
Sylvain Poinard ◽  
Philippe Gain ◽  
Gilles Thuret ◽  
Zhiguo He

2015 ◽  
Vol 2015 ◽  
pp. 1-19 ◽  
Author(s):  
Beatriz E. Ramírez ◽  
Ana Sánchez ◽  
José M. Herreras ◽  
Itziar Fernández ◽  
Javier García-Sancho ◽  
...  

Objective. To evaluate outcomes of cultivated limbal epithelial transplantation (CLET) for management of ocular surface failure due to limbal stem cell deficiency (LSCD).Design. Prospective, noncomparative, interventional case series and extensive comparison with recent similar studies.Participants. Twenty eyes with LSCD underwent CLET (11 autologous; 9 allogeneic) and were followed up for 3 years. Etiologies were divided into 3 prognostic categories: Group 1, chemical injuries (7 eyes); Group 2, immune-based inflammation (4 eyes); and Group 3, noninflammatory diseases (9 eyes).Intervention. Autologous and allogeneic limbal epithelial cells were cultivated on amniotic membranes and transplanted. Evaluations were based on clinical parameters, survival analysis, and in vivo confocal microscopy (IVCM). European Union Tissues/Cells Directive and good manufacturing procedures were followed.Main Outcome Measures. Improved clinical parameters, absence of epithelial defects, and improved central corneal epithelial phenotype.Results. Success rate was 80% at 1-2 years and 75% at 3 years. Autografts and allografts had similar survival. Success rate was significantly lower in prognostic Group 1 (42.9%) than in Groups 2-3 (100% each). All clinical parameters improved substantially. By IVCM, 80% of cases improved in epithelial status.Conclusions. CLET improved corneal epithelium quality, with subsequent improvement in symptoms, quality of life, and vision. These results confirm that CLET is a valid therapy for ocular surface failure.


2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Tiago Ramos ◽  
Deborah Scott ◽  
Sajjad Ahmad

The human ocular surface (front surface of the eye) is formed by two different types of epithelia: the corneal epithelium centrally and the conjunctival epithelium that surrounds this. These two epithelia are maintained by different stem cell populations (limbal stem cells for the corneal epithelium and the conjunctival epithelial stem cells). In this review, we provide an update on our understanding of these epithelia and their stem cells systems, including embryology, new markers, and controversy around the location of these stem cells. We also provide an update on the translation of this understanding into clinical applications for the treatment of debilitating ocular surface diseases.


Cornea ◽  
2003 ◽  
Vol 22 (1) ◽  
pp. 70-71 ◽  
Author(s):  
Takahiro Nakamura ◽  
Noriko Koizumi ◽  
Masakatsu Tsuzuki ◽  
Keiko Inoki ◽  
Yoichiro Sano ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-7 ◽  
Author(s):  
Ying Dong ◽  
Han Peng ◽  
Robert M. Lavker

Identification and characterization of the limbal epithelial stem cells (LESCs) has proven to be a major accomplishment in anterior ocular surface biology. These cells have been shown to be a subpopulation of limbal epithelial basal cells, which serve as the progenitor population of the corneal epithelium. LESCs have been demonstrated to play an important role in maintaining corneal epithelium homeostasis. Many ocular surface diseases, including intrinsic (e.g., Sjogren’s syndrome) or extrinsic (e.g., alkali or thermal burns) insults, which impair LESCs, can lead to limbal stem cell deficiency (LSCD). LSCD is characterized by an overgrowth of conjunctival-derived epithelial cells, corneal neovascularization, and chronic inflammation, eventually leading to blindness. Treatment of LSCD has been challenging, especially in bilateral total LSCD. Recently, advances in LESC research have led to novel therapeutic approaches for treating LSCD, such as transplantation of the cultured limbal epithelium. These novel therapeutic approaches have demonstrated efficacy for ocular surface reconstruction and restoration of vision in patients with LSCD. However, they all have their own limitations. Here, we describe the current status of LSCD treatment and discuss the advantages and disadvantages of the available therapeutic modalities.


Author(s):  
Minghong Gao ◽  
Yingxin Chen ◽  
Fengying Zhai ◽  
Zhiling Liu ◽  
Qiming Liu ◽  
...  

IntroductionOral epithelial cells were recently shown to be able to differentiate into corneal epithelium and the efficacy of CAOMEC has been suggested by the presence of epithelium replacement. Therefore, the aim was to evaluate the treatment outcome in limbal stem cell deficiency (LSCD) by adding the CAOMEC to the regular amniotic membrane (AM) treatment.Material and methodsEyes with LSCD were randomized in two groups to undergo either CAOMECS combined with AM transplantation (A group) or AM transplantation alone (B group). Clinical outcome measures were corneal epithelium healing, best corrected visual acuity, symblepharon, corneal transparency, corneal neovascularization and ocular surface inflammation.ResultsThe normal corneal epithelialization rate in group A (73.33%) was higher than that in group B (35.48%), and the average healing time was shorter (3.45 ± 2.12 w vs.4.64 ± 1.63). The symblepharon in above two groups were improved in the first 3 m after surgery, however, after 6 m, part of the B group had recurrence. In improving corneal transparency, group A has obvious advantages. Corneal neovascularization (CNV) was improved to some extent in the first 3 m after surgery, but group A (1.47 ± 0.64) was better than group B (1.94 ± 0.85) after 6 m. Both groups can improve the inflammatory state to some extent.ConclusionsThe transplantation of CAOMECS offers a viable and safe alternative in the reconstruction of a stable ocular surface. The effect is better than that of traditional AM transplantation, mainly in promoting corneal epithelialization, improving ocular surface structure, reducing fiber and vascular infiltration.


1995 ◽  
Vol 35 (4) ◽  
pp. 182
Author(s):  
Kazuo Tsubota ◽  
Ikuko Toda ◽  
Hiroshi Saito ◽  
Naoshi Shinozaki ◽  
Jun Shimazaki

Sign in / Sign up

Export Citation Format

Share Document